Modelling the therapeutic potential of tonabersat

In this preclinical study, we evaluated the possible therapeutic potential of tonabersat for the treatment of glioblastoma. Tonabersat is a benzopyran derivate that binds to a unique stereoselective binding site in astrocytes and inhibits gap-junction-mediated processes, which has been observed between tumor cells, between astrocytes, and between tumor cells and astrocytes. Gap-junction-directed therapy using a pharmacological suppressor or modulator, such as tonabersat, could be a promising target in the treatment of glioblastoma.

Read more:

De Meulenaere, Valerie, Ellen Bonte, Jeroen Verhoeven, Jean-Pierre Kalala Okito, Leen Pieters, Anne Vral, Olivier De Wever, Luc Leybaert, Ingeborg Goethals, Christian Vanhove, Benedicte Descamps, and Karel Deblaere. 2019. “Adjuvant Therapeutic Potential of Tonabersat in the Standard Treatment of Glioblastoma : A Preclinical F98 Glioblastoma Rat Model Study.” PLOS ONE 14 (10).

http://doi.org/10.1371/journal.pone.0224130